Wong C R, Njei B, Nguyen M H, Nguyen A, Lim J K
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA.
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069. doi: 10.1111/apt.14342. Epub 2017 Sep 28.
Non-alcoholic fatty liver disease (NAFLD) is expected to become a leading aetiology of hepatocellular carcinoma (HCC)-related mortality in the United States. HCC treatments with curative intent (OLT, orthotopic liver transplantation; resection; RFA, radiofrequency ablation) can improve survival in carefully selected patients.
To compare survival after receipt of curative treatment for NAFLD and non-NAFLD-HCC aetiologies (HCV, chronic hepatitis C; HBV, chronic hepatitis B; ALD, alcoholic liver disease) and by treatment was performed.
A cohort of 17 664 patients was assembled using linked Surveillance, Epidemiology, and End Results and Medicare data from 1991 to 2011 with confirmed diagnosis of HCC.
The cohort was mostly male, aged 70 (21-106) years, without cardiovascular disease, and had liver cirrhosis without decompensation, metastatic HCC or large tumour size (>5 cm). The NAFLD-HCC group was mostly female and older with more cardiovascular disease, metastatic HCC, and large tumour size and less cirrhosis and decompensated liver disease than the non-NAFLD-HCC groups. The NAFLD group was 47% less likely to receive any curative treatment as compared with non-NAFLD aetiologies (OR 0.53, P < .001). NAFLD-HCC had worse median survival after OLT (3.2, 0-12.9 years, P = .01) but had improved survival after resection (2.4, 0-12.0 years, P < .001) as compared with non-NAFLD-HCC. No significant survival differences existed for RFA by HCC aetiology. NAFLD was not an independent predictor of mortality after OLT, resection or RFA.
Patients with NAFLD-HCC had worse survival after OLT but favourable survival after resection, particularly in the absence of cirrhosis, as compared with non-NAFLD-HCC aetiologies.
非酒精性脂肪性肝病(NAFLD)预计将成为美国肝细胞癌(HCC)相关死亡的主要病因。具有治愈意图的HCC治疗方法(原位肝移植、肝切除术、射频消融)可提高精心挑选患者的生存率。
比较接受NAFLD和非NAFLD-HCC病因(丙型肝炎病毒、慢性丙型肝炎;乙型肝炎病毒、慢性乙型肝炎;酒精性肝病)的治愈性治疗后的生存率,并按治疗方法进行比较。
利用1991年至2011年的监测、流行病学和最终结果以及医疗保险数据,组建了一个包含17664例确诊HCC患者的队列。
该队列主要为男性,年龄70(21-106)岁,无心血管疾病,患有无失代偿的肝硬化、转移性HCC或肿瘤较大(>5cm)。与非NAFLD-HCC组相比,NAFLD-HCC组女性居多且年龄较大,心血管疾病、转移性HCC和肿瘤较大的情况更多,肝硬化和失代偿性肝病的情况更少。与非NAFLD病因相比,NAFLD组接受任何治愈性治疗的可能性低47%(比值比0.53,P<.001)。与非NAFLD-HCC相比,NAFLD-HCC原位肝移植后的中位生存期较差(3.2年,0-12.9年,P=.01),但肝切除术后生存期有所改善(2.4年,0-12.0年,P<.001)。按HCC病因分类,射频消融术后生存率无显著差异。NAFLD不是原位肝移植、肝切除或射频消融术后死亡的独立预测因素。
与非NAFLD-HCC病因相比,NAFLD-HCC患者原位肝移植后的生存期较差,但肝切除术后生存期良好,尤其是在无肝硬化的情况下。